(:AERI)
Business Focus: N/A
Nov 22, 2022 01:01 am ET
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has completed its acquisition of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”). This transaction helps bolster Alcon’s presence in the ophthalmic pharmaceutical space with its growing portfolio of commercial products and development pipeline.
Nov 03, 2022 04:01 pm ET
Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the third quarter ended September 30, 2022.
Oct 28, 2022 08:00 am ET
SHAREHOLDER ALERT: Weiss Law Reminds AERC, SMBC, CSVI, and AERI Shareholders About Its Ongoing Investigations
NEW YORK, Oct. 28, 2022 /PRNewswire/ --
Oct 25, 2022 10:45 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SBTX, POSH, PBFX, RNWK, AERI
NEW YORK, Oct. 25, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Oct 24, 2022 03:25 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – ECOM, SBTX, PZN, AERI
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Oct 23, 2022 10:23 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERI
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hill International, Inc. (NYSE: HIL)’s...
Oct 18, 2022 05:00 pm ET
INVESTOR ALERT: The M&A Class Action Firm Continues Investigating the Merger – AERI, CYBE, RFP, AAWW
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Oct 17, 2022 06:19 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CSVI, AERI, BTRS, POSH
NEW YORK, Oct. 17, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Oct 16, 2022 09:50 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CSVI, AERI, RCKT, RCOR
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Computer Services, Inc. (OTCQX:...
Oct 14, 2022 06:18 pm ET
AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. -
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Aerie Pharmaceuticals, Inc. (NasdaqGM: AERI) to Alcon Inc. (NYSE: ALC). Under the terms of the proposed transaction, shareholders of Aerie will receive $15.25 in cash for each share of Aerie that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Oct 10, 2022 08:47 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AERI, SMBC, EVOP
NEW YORK, Oct. 10, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Oct 07, 2022 04:44 pm ET
SHAREHOLDER ALERT: Weiss Law Reminds SMBC, AERI, CSVI, and COWN Shareholders About Its Ongoing Investigations
NEW YORK, Oct. 7, 2022 /PRNewswire/ --
Oct 05, 2022 08:00 am ET
SHAREHOLDER ALERT: Weiss Law Reminds AERI, RCOR, STOR, and LOTZ Shareholders About Its Ongoing Investigations
NEW YORK, Oct. 5, 2022 /PRNewswire/ --
Oct 03, 2022 10:50 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EVOP, AERI, FMTX, CSVI
NEW YORK, Oct. 3, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Sep 30, 2022 04:09 pm ET
SHAREHOLDER ALERT: Weiss Law Reminds SMBC, AERI, CSVI, and COWN Shareholders About Its Ongoing Investigations
NEW YORK, Sept. 30, 2022 /PRNewswire/ --
Sep 28, 2022 06:10 pm ET
SHAREHOLDER ALERT: Weiss Law Reminds RCOR, STOR, AERI, and LOTZ Shareholders About Its Ongoing Investigations
NEW YORK, Sept. 28, 2022 /PRNewswire/ --
Sep 28, 2022 01:14 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AERI, ECOM, PFS, LBAI
NEW YORK, Sept. 28, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Sep 27, 2022 02:23 pm ET
AERIE PHARMACEUTICALS - INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. -
NEW ORLEANS, Sept. 27, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Aerie Pharmaceuticals, Inc. (NasdaqGM: AERI) to Alcon Inc. (NYSE: ALC). Under the terms of the proposed transaction, shareholders of Aerie will receive $15.25 in cash for each share of Aerie that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Sep 27, 2022 12:22 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AERI, TRQ, SGFY, ECOM
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Aerie Pharmaceuticals, Inc. (NASDAQ:...
Sep 26, 2022 09:55 am ET
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger – VIVO, AERI, CYBE, GMTX
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and...
Sep 24, 2022 01:00 pm ET
EQUITY ALERT: The M&A Class Action Firm Launches Merger Inquiry - VIVO, AERI, CYBE, GMTX
NEW YORK, Sept. 24, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Sep 23, 2022 02:41 pm ET
SHAREHOLDER ALERT: Weiss Law Reminds FMTX, IEA, AERI, and VIVO Shareholders About Its Ongoing Investigations
NEW YORK, Sept. 23, 2022 /PRNewswire/ --
Sep 22, 2022 12:56 pm ET
The M&A Class Action Firm Continues Investigating the Merger – VIVO, AERI, CYBE, GMTX
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Sep 22, 2022 09:40 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FTAI, HIL, CSVI, AERI
NEW YORK, Sept. 22, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Sep 21, 2022 04:22 pm ET
SHAREHOLDER ALERT: Weiss Law Reminds AERI, CSVI, EVOP, and HIL Shareholders About Its Ongoing Investigations
NEW YORK, Sept. 21, 2022 /PRNewswire/ --
Sep 16, 2022 09:15 am ET
INVESTIGATION ALERT: Halper Sadeh LLC Investigates EVOP, HIL, CSVI, AERI
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments, Inc. (NASDAQ: EVOP)’s...
Sep 15, 2022 05:50 pm ET
SHAREHOLDER ALERT: Weiss Law Reminds AERI, CSVI, EVOP, and HIL Shareholders About Its Ongoing Investigations
NEW YORK, Sept. 15, 2022 /PRNewswire/ --
Sep 13, 2022 08:00 am ET
Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that it will host a Key Opinion Leader (KOL) webinar on Friday, September 23, 2022 from 10:00 a.m. – 11:30 a.m. Eastern Time.
Sep 12, 2022 12:00 am ET
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates CSVI, AERI, SGFY, ECOM
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Sep 08, 2022 04:08 pm ET
SHAREHOLDER ALERT: Weiss Law Reminds AERI, CSVI, EVOP, and HIL Shareholders About Its Ongoing Investigations
NEW YORK, Sept. 8, 2022 /PRNewswire/ --
Aug 31, 2022 01:16 pm ET
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates CCXI, HIL, CSVI, AERI
NEW YORK, Aug. 31, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Aug 30, 2022 12:50 pm ET
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Aerie Pharmaceuticals, Inc. (Nasdaq - AERI)
Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Aerie Pharmaceuticals, Inc. (“Aerie” or the “Company”) (Nasdaq – AERI) for possible breaches of fiduciary duty and other violations...
Aug 29, 2022 05:45 pm ET
SHAREHOLDER ALERT: Weiss Law Reminds AERI, CSVI, HIL, and CYBE Shareholders About Its Ongoing Investigations
NEW YORK, Aug. 29, 2022 /PRNewswire/ --
Aug 29, 2022 09:00 am ET
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates CSVI, ONEM, AERI, SFT
Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Computer Services, Inc. (OTCQX:...
Aug 25, 2022 11:26 am ET
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates ONEM, CCXI, AERI, SFT
NEW YORK, Aug. 25, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Aug 24, 2022 10:42 pm ET
AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. -
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Aerie Pharmaceuticals, Inc. (NasdaqGM: AERI) to Alcon Inc. (NYSE: ALC). Under the terms of the proposed transaction, shareholders of Aerie will receive $15.25 in cash for each share of Aerie that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Aug 24, 2022 08:20 pm ET
The M&A Class Action Firm Announces the Investigation of Aerie Pharmaceuticals, Inc. – AERI
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Aug 24, 2022 08:19 am ET
AERI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Aerie Pharmaceuticals, Inc. Is Fair to Shareholders
Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) to Alcon for $15.25 per share is fair to Aerie shareholders.
Aug 23, 2022 03:20 pm ET
SHAREHOLDER ALERT: Weiss Law Investigates Aerie Pharmaceuticals, Inc.
NEW YORK, Aug. 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Aerie Pharmaceuticals, Inc. ("Aerie" or the "Company") (NASDAQ: AERI), in connection with the proposed acquisition of the Company by Alcon Inc. (NYSE: ALC). Under the terms of the merger agreement, the Company's shareholders will receive $15.25 in cash for each share of Aerie common stock owned. The transaction is valued at approximately $770 million.
Aug 23, 2022 09:34 am ET
Thinking about buying stock in FuboTV, Aerie Pharmaceuticals, Waitr, Tilray, or AMC Entertainment?
NEW YORK, Aug. 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FUBO, AERI, WTRH, TLRY, and AMC.
Aug 23, 2022 09:23 am ET
Shareholder Alert: Ademi LLP investigates whether Aerie Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Alcon
MILWAUKEE, Aug. 23, 2022 /PRNewswire/ -- Ademi LLP is investigating Aerie (NASDAQ: AERI) for possible breaches of fiduciary duty and other violations of law in its transaction with Alcon.
Aug 22, 2022 09:18 pm ET
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”), a pharmaceutical company focused on the discovery, development, manufacturing and commercialization of first-in-class ophthalmic therapies, today announced the companies have entered into a definitive merger agreement through which Alcon will acquire Aerie. This transaction affirms Alcon’s commitment to the ophthalmic pharmaceutical space and is expected to add broader pharmaceutical R&D capabilities to Alcon’s existing commercial expertise,
Aug 15, 2022 06:30 am ET
Aerie Pharmaceuticals Announces New Employee Inducement Grant
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced that the compensation committee of Aerie Pharmaceutical’s board of directors granted one new employee an award totaling 16,900 stock options that will vest over 4 years, with 25% vesting on the first anniversary of the hire date and the remainder vesting ratably on each of the subsequent 36 monthly anniversaries o
Aug 04, 2022 04:01 pm ET
Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the second quarter ended June 30, 2022 and provides its business and pipeline objectives and financial guidance for 2022 and beyond, including its expectation to achieve cash flow break even during 2024.
Aug 01, 2022 04:01 pm ET
Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that the first participant has been dosed in the Phase 3 registrational “COMET-3” study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED). COMET-3 is the second of three trials in the Phase 3 registrational program for AR-15512. Aerie plans to initiate the last of the trials, the COMET-4 safety study, in the fourth quarter of 2022. Aerie intends t
Jul 28, 2022 06:10 pm ET
Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ET
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present second quarter 2022 financial results after the market closes Thursday, August 4, 2022.
Jul 08, 2022 06:30 am ET
Aerie Pharmaceuticals Announces New Employee Inducement Grant
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced that the compensation committee of Aerie Pharmaceutical’s board of directors granted one new employee an award totaling 16,900 stock options that will vest over 4 years, with 25% vesting on the first anniversary of the hire date and the remainder vesting ratably on each of the subsequent 36 monthly anniversaries o
May 25, 2022 04:30 pm ET
Aerie Pharmaceuticals to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Raj Kannan, Chief Executive Officer, along with Peter Lang, Chief Financial Officer, and Dr. Gary Sternberg, Chief Medical Officer, will present at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. Eastern Time in New York City, NY.
May 24, 2022 07:30 am ET
Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that the first participant has been dosed in the Phase 3 registrational “COMET-2” study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED). COMET-2 is the first of three trials in the Phase 3 registrational program for AR-15512. Aerie plans to initiate the other two trials in the second half of 2022 in support of a potential New Drug Application (N
May 05, 2022 04:01 pm ET
Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today reports financial results for the first quarter ended March 31, 2022 and reaffirms the business and pipeline objectives and financial guidance previously reported for 2022.
Apr 28, 2022 04:35 pm ET
Aerie Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022 at 5:00 p.m. ET
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present first quarter 2022 financial results after the market closes Thursday, May 5, 2022.
Apr 26, 2022 04:05 pm ET
Aerie Pharmaceuticals Announces Presentations at the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, Colorado, May 1-4, 2022
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that fourteen abstracts related to Aerie’s Rhopressa®/netarsudil, AR-15512 in dry eye and “ROCK’Sters” anti-inflammatory programs will be presented at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2022) in Denver, Colorado, May 1 through 4, 2022.
Apr 20, 2022 04:05 pm ET
Aerie Pharmaceuticals Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., April 22-26, 2022
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that three abstracts will be presented at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., on April 22 through 26, 2022.
Apr 06, 2022 04:30 pm ET
Aerie Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 p.m. ET
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Raj Kannan, Chief Executive Officer, along with Peter Lang, Chief Financial Officer, and Dr. Gary Sternberg, Chief Medical Officer, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 p.m. Eastern Time.
Mar 18, 2022 07:00 am ET
Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Peter F. Lang will join the Company as Chief Financial Officer, effective March 18, 2022. He will report to Raj Kannan, Chief Executive Officer of Aerie Pharmaceuticals and become a member of the Aerie Executive Committee.
Feb 24, 2022 04:01 pm ET
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a business update and financial guidance for 2022.
Feb 24, 2022 06:30 am ET
Aerie Pharmaceuticals Appoints Gary Sternberg, M.D., M.B.A. as Chief Medical Officer
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Gary Sternberg, M.D., M.B.A., will join the Company as Chief Medical Officer (CMO), effective March 1, 2022. He will report to Raj Kannan, Chief Executive Officer of Aerie Pharmaceuticals and become a member of the Aerie Executive Committee.
Feb 17, 2022 04:45 pm ET
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022 at 5:00 p.m. ET
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that its fourth quarter and full year 2021 financial results will be released after the market closes on Thursday, February 24, 2022.
Dec 22, 2021 04:01 pm ET
Aerie Pharmaceuticals Reports Inducement Grant to Chief Executive Officer Under Nasdaq Listing Rule 5635(c)(4)
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reports an inducement grant to Chief Executive Officer, Raj Kannan, appointed on December 16, 2021 with a start date of December 20, 2021.
Dec 16, 2021 06:30 am ET
Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today announced that Raj Kannan will join the Company as Chief Executive Officer and a director, effective December 20, 2021.
Dec 07, 2021 02:00 am ET
Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Aerie and Santen have entered into an exclusive development and commercialization agreement for Rhopressa®/Rhokiinsa® (netarsudil ophthalmic solution) 0.02% and Rocklatan®/Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. The expanded collaboration includes Europe, Commonwealth of Independent States (CIS) countries, China, India, parts of Latin America and the Oceania countries.
Nov 09, 2021 04:30 pm ET
Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Benjamin McGraw, III, Pharm.D., Interim Executive Chairman, will participate in the following virtual investor conferences.
Nov 04, 2021 04:01 pm ET
Aerie Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today reported financial results for the third quarter ended September 30, 2021 and provided a general business update.
Oct 28, 2021 07:30 am ET
Aerie Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call on Thursday, November 4, 2021
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, announced today that its third quarter 2021 financial results will be released after the market closes on Thursday, November 4, 2021. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update.
Oct 21, 2021 04:01 pm ET
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Glaucoma Innovation Showcase
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that Tom Mitro, President and Chief Operating Officer presented an overview on Aerie’s glaucoma franchise at the Ophthalmology Innovation Summit Glaucoma Innovation Showcase. The slide presentation provides an update on Aerie’s franchise growth in the United States, as well as progress toward market entry in Europe and Japan.
Oct 12, 2021 08:32 am ET
Thinking about buying stock in Ocugen, aTyr Pharma, Nextplay Technologies, Aerie Pharmaceuticals, or Nutriband?
NEW YORK, Oct. 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OCGN, LIFE, NXTP, AERI, and NTRB.
Oct 12, 2021 06:30 am ET
Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today reported positive topline results for the Company’s Phase 3 clinical trial in Japan evaluating netarsudil ophthalmic solution 0.02% (“netarsudil 0.02%”) versus ripasudil hydrochloride hydrate ophthalmic solution 0.4% (“ripasudil 0.4%”). The results showed that netarsudil 0.02% once daily was superior to ripasudil 0.4% twice daily in lowering intraocular pressure (“IOP”) at week four (p
Oct 07, 2021 04:01 pm ET
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Retina Innovation Showcase
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that Casey Kopczynski, Ph.D., Chief Scientific Officer presented an overview on Aerie’s retina product candidates, at the Ophthalmology Innovation Summit Retina Innovation Showcase. The slide presentation addresses Aerie’s proprietary PRINT® drug delivery platform and retina product candidates AR-1105 (dexamethasone implant, Phase 3 ready), AR-13503 (Rho kinase/Protein kinase C inhibitor implant, Phase 2a), and AR-14034 (pan-VEGF receptor inhibitor implant, preclinical).
Oct 06, 2021 07:30 am ET
Aerie Pharmaceuticals Announces Presentation at the 39th Annual Scientific Meeting of the American Society of Retina Specialists
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that topline results from the AR-1105 (dexamethasone intravitreal implant) Phase 2 clinical trial in patients with macular edema due to retinal vein occlusion will be presented at the 39th Annual Scientific Meeting of the American Society of Retina Specialists in San Antonio, Texas.
Sep 27, 2021 07:30 am ET
Aerie Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Benjamin F. McGraw, III, Pharm.D., Interim Executive Chairman and David A. Hollander, M.D., M.B.A., Chief R&D Officer, will participate in a fireside discussion at the virtual Cantor Global Healthcare Conference on Tuesday, September 28, 2021 at 8:40 a.m. Eastern Time. Dr. McGraw and Dr. Hollander will
Sep 21, 2021 06:30 am ET
Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that it is executing its succession plan for its long-serving Chairman and CEO and that effective September 17, 2021, Vicente Anido, PhD. no longer serves as the Company’s Chairman and Chief Executive Officer or as a director of the Company. Consistent with the succession plan in place, the Company’s Board of Directors has appointed Benjamin F. McGraw, III, Pharm.D. as its Interim Executive Chairman of the Board of Directors of the Company and commenced a search for a new Chief Executive Officer.
Sep 20, 2021 06:30 am ET
Aerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug Disposition
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment Erik Pacyniak, Ph.D., D.A.B.T., Director, Toxicology, reporting to Jeff White, Ph.D., D.A.B.T., Aerie’s Vice President of Research and Discovery. Dr. Pacyniak will oversee all aspects of nonclinical toxicology and drug disposition for Aerie. He most recently held a related nonclinical safety assess
Sep 15, 2021 04:01 pm ET
Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 (TRPM8 Agonist) Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms and Signs in Successful Phase 2b C
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported positive topline results of its Phase 2b clinical study, named COMET-1, for AR-15512 (TRPM8 Agonist) (“AR-15512”) ophthalmic solution for the treatment of patients with dry eye disease. Management will host a conference call and provide accompanying slides to discuss these results at 5:00 p.m. ET today.
Sep 13, 2021 06:30 am ET
Aerie Pharmaceuticals Announces Appointment of Carolyn McAuliffe, Senior Director, Communications
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment of Carolyn McAuliffe, Senior Director, Communications, reporting to Tad Heitmann, Aerie’s Vice President of Marketing. Ms. McAuliffe will be responsible for the development and execution of Aerie’s marketing and medical communications activities. She most recently held a related position at Masimo
Sep 07, 2021 07:30 am ET
Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will participate in the following virtual investor conferences.
Sep 07, 2021 06:30 am ET
Aerie Pharmaceuticals Announces Appointment of Michael Bradley, Senior Director, Manufacturing
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment of Michael Bradley, Senior Director, Manufacturing, reporting to Site Director, Athlone. Mr. Bradley will be responsible for manufacturing and supply chain operations at Aerie’s manufacturing facility in Athlone, Ireland. He most recently held related positions at Norbrook and Zoetis.
Aug 12, 2021 07:30 am ET
Aerie Pharmaceuticals to Participate in the H.C. Wainwright Ophthalmology Conference
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Casey C. Kopczynski, Ph.D., Chief Scientific Officer, will participate in a virtual panel discussion titled, “What are the Greatest Unmet Needs Facing Ophthalmology Today?”, at the H.C. Wainwright Ophthalmology Conference. The panel will be held on Tuesday, August 17, 2021 at 9:00 a.m. Eastern Time.
Aug 04, 2021 04:01 pm ET
Aerie Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a general business update.
Jul 28, 2021 07:30 am ET
Aerie Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call on Wednesday, August 4, 2021
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its first quarter 2021 financial results will be released after the market closes on Wednesday, August 4, 2021. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update.
Jul 20, 2021 04:01 pm ET
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit European Innovation Showcase
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that David A. Hollander, M.D., M.B.A., Chief Research & Development Officer presented an overview on Aerie’s globalization outlook at the Ophthalmology Innovation Summit European Innovation Showcase. The slide presentation includes an overview on Aerie’s approach to Europe for both its glaucoma franchise and Aer
Jul 15, 2021 06:30 am ET
Aerie Pharmaceuticals Announces Appointment of Leon J. Atencia, Director of Regulatory Affairs
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment of Leon J. Atencia, Director of Regulatory Affairs, reporting to Emma Beausang, Aerie’s Vice President of Regulatory Affairs. Mr. Atencia will be responsible for clinical regulatory affairs and oversee post-marketing and pharmacovigilance activities. He most recently held a related position at Reva
Jun 21, 2021 07:00 am ET
Aerie Pharmaceuticals Announces Appointment of Frank Estrada, Ed.D., as Director, Salesforce Training
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment of Frank Estrada, Ed.D., as Director, Salesforce Training, reporting to Evan Hockman, Aerie’s Vice President of Sales. Dr. Estrada will design, develop and implement the training curriculum for both Territory Sales Managers and the Sales Management Team across the United States. He most recently he
Jun 21, 2021 06:45 am ET
Aerie Pharmaceuticals to Participate in the Raymond James Human Health Innovation Conference – UPDATED RELEASE
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Raymond James Human Health Innovation Conference on Tuesday, June 22, 2021 at 1:20 p.m. Eastern Time. In addition to providing an Aerie overview and business update, Dr. Anido will discuss updated s
Jun 17, 2021 06:30 am ET
Aerie Pharmaceuticals Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil Ophthalmic Solution in Japan
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the completion of patient enrollment for its first Phase 3 clinical trial of netarsudil ophthalmic solution in Japan, comparing netarsudil ophthalmic solution 0.02% (“netarsudil”), administered once a day in the evening, to ripasudil hydrochloride hydrate ophthalmic solution 0.4% (“ripasudil”), marketed as Glana
Jun 15, 2021 07:30 am ET
Aerie Pharmaceuticals to Participate in the Raymond James Human Health Innovation Conference
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Raymond James Human Health Innovation Conference on Tuesday, June 22, 2021 at 1:20 p.m. Eastern Time. Dr. Anido will provide an Aerie overview and business update.
May 06, 2021 07:30 am ET
Aerie Pharmaceuticals to Participate in the Bank of America Securities 2021 Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Bank of America Securities 2021 Healthcare Conference on Wednesday, May 12, 2021 at 9:30 a.m. Eastern Time. Dr. Anido will provide an Aerie overview and business update.
May 05, 2021 04:01 pm ET
Aerie Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported financial results for the first quarter ended March 31, 2021 and provided a general business update.
Apr 29, 2021 06:30 am ET
Aerie Pharmaceuticals Completes Enrollment of its Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the completion of patient enrollment for COMET-1, a Phase 2b clinical trial of AR-15512 (TRPM8 Agonist) (“AR-15512”) ophthalmic solution for the treatment of patients with dry eye disease.
Apr 28, 2021 07:30 am ET
Aerie Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call on Wednesday, May 5, 2021
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its first quarter 2021 financial results will be released after the market closes on Wednesday, May 5, 2021. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update.
Apr 28, 2021 06:30 am ET
Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced it will participate and have poster presentations at the virtual Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting, to be held May 1-7, 2021. The posters will highlight topics ranging from additional research findings on netarsudil to potential new product candidates such as the new clas
Apr 19, 2021 06:30 am ET
Aerie Pharmaceuticals Receives Marketing Authorisation of Roclanda® 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) in Great Britain
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Roclanda® 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) (“Roclanda®”) has received marketing authorisation from the Medicines and Healthcare Products Regulatory Agency (“MHRA”) in Great Britain. Roclanda® is indicated for the reduction o
Apr 07, 2021 07:30 am ET
Aerie Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 12:45 p.m. Eastern Time. Dr. Anido will provide an Aerie overview and business update.
Mar 30, 2021 08:05 am ET
Aerie Pharmaceuticals Announces Publication of Peer-Reviewed Paper Evaluating the Treatment Effect of Netarsudil on Outflow Function in Steroid-Induced Glaucoma
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the publication of a peer-reviewed paper in eLife, a science journal, entitled, “Antifibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis.” This paper evaluates the treatment effect of netarsudil, marketed as Rhopressa® (netarsudil ophthalmic solut
Mar 11, 2021 04:01 pm ET
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Dry Eye Innovation Showcase
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that David A. Hollander, M.D., M.B.A., Chief Research & Development Officer presented an overview on AR-15512, Aerie’s dry eye product candidate, at the Ophthalmology Innovation Summit Dry Eye Innovation Showcase. The slide presentation includes additional details on the Phase 2a study and the role of TRPM8 as a
Mar 11, 2021 07:30 am ET
Aerie Pharmaceuticals to Participate in the Oppenheimer 31st Annual Virtual Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Richard J. Rubino, Chief Financial Officer, will present in a fireside discussion at the Oppenheimer 31st Annual Virtual Healthcare Conference on Wednesday, March 17, 2021 at 8:00 a.m. Eastern Time. Mr. Rubino will provide an Aerie overview and business update.
Feb 25, 2021 04:01 pm ET
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a general business update.
Feb 22, 2021 07:30 am ET
Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Company will participate in the following virtual investor conferences.
Feb 18, 2021 07:30 am ET
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its fourth quarter and full year 2020 financial results will be released after the market closes on Thursday, February 25, 2021. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business
Jan 11, 2021 06:30 am ET
Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the European Commission (EC) has granted a marketing authorisation for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prosta
Nov 13, 2020 06:50 am ET
Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the European Union
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorisation application (MAA) for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. The recommended indication is t
Nov 10, 2020 07:30 am ET
Aerie Pharmaceuticals to Participate in the Stifel 2020 Virtual Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020 at 8:00 a.m. Eastern Time. Dr. Anido will provide an Aerie overview and a business update.
Nov 05, 2020 04:01 pm ET
Aerie Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported financial results for the third quarter ended September 30, 2020 and provided a general business update.
Oct 29, 2020 06:30 am ET
Aerie Pharmaceuticals Initiates Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the commencement of COMET-1, a Phase 2b clinical trial of AR-15512 (TRPM8 agonist) ophthalmic solution for the treatment of patients with dry eye disease.
Oct 28, 2020 03:00 am ET
Santen and Aerie Conclude Exclusive License Agreement for Rhopressa® and Rocklatan® in Japan and Several Other Asian Countries
Santen Pharmaceutical Co., Ltd. (“Santen”) and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Santen and Aerie have entered into an exclusive development and commercialization agreement for Rhopressa® and Rocklatan® in Japan, along with rights for several other Asian countries.
Oct 27, 2020 07:30 am ET
Aerie Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host Conference Call on Thursday, November 5, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its third quarter 2020 financial results will be released after the market closes on Thursday, November 5, 2020. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update.
Sep 29, 2020 06:30 am ET
Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-15512 (TRPM8 Agonist) Eye Drop for Dry Eye Disease
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has reviewed the Investigational New Drug Application (IND) for AR-15512 (TRPM8 agonist) eye drop for dry eye and it is now in effect, allowing Aerie to initiate clinical studies in the treatment of dry eye. Aerie expects to initiate a Phase 2b clinical study in t
Sep 24, 2020 06:30 am ET
Aerie Pharmaceuticals Announces Successful Interim 90-Day Topline Data From Its Six-Month Mercury 3 Clinical Trial in Europe
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced successful interim 90-day topline data from its six-month Phase 3b clinical trial in Europe known as Mercury 3, comparing Roclanda® to Ganfort®.
Sep 15, 2020 06:45 am ET
Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rhopressa® (netarsudil ophthalmic solution) 0.02%
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that its sterile fill production facility in Athlone, Ireland has received approval from the U.S. Food and Drug Administration (FDA) for production of Rhopressa® (netarsudil ophthalmic solution) 0.02% for commercial distribution in the United States. This approval comes following the FDA review of the
Sep 08, 2020 07:30 am ET
Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Company will participate in the following virtual investor conferences in September.
Aug 06, 2020 04:01 pm ET
Aerie Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported financial results for the second quarter ended June 30, 2020 and provided a general business update.
Jul 30, 2020 07:30 am ET
Aerie Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its second quarter 2020 financial results will be released after the market closes on Thursday, August 6, 2020. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update.
Jul 27, 2020 06:30 am ET
Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 (Dexamethasone Intravitreal Implant) Phase 2 Clinical Trial in Patients with Macular Edema Due to Retinal Vein Occlusion
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported positive topline results for the Company’s Phase 2 clinical trial evaluating AR-1105 (dexamethasone intravitreal implant) in patients with macular edema associated with retinal vein occlusion.
Jun 11, 2020 06:30 am ET
Aerie Pharmaceuticals Appoints Peter J. McDonnell, M.D., to the Company’s Board of Directors
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and potentially other diseases of the eye, today announced that Peter J. McDonnell, M.D., has been appointed to the Company’s Board of Directors and will also be a member of both the Nominating and Corporate Governance and Compensation Committees of the Board.
May 06, 2020 04:01 pm ET
Aerie Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and potentially other diseases of the eye, today reported financial results for the first quarter ended March 31, 2020 and provided a general business update, including the impact of the COVID-19 pandemic on company operations.
May 05, 2020 07:30 am ET
Aerie Pharmaceuticals to Present at the Bank of America Securities 2020 Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Bank of America Securities 2020 Healthcare Conference on Tuesday, May 12, 2020 at 8:20 a.m. Eastern Time. Dr. Anido will provide an Aerie overview and business update.
Apr 29, 2020 07:30 am ET
Aerie Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye announced today that its first quarter 2020 financial results will be released after the market closes on Wednesday, May 6, 2020. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update.
Apr 09, 2020 04:01 pm ET
Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated with COVID-19
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today provided a business update associated with the impact of the global Coronavirus disease (COVID-19) pandemic on Company operations.
Apr 07, 2020 07:30 am ET
Aerie Pharmaceuticals to Present at the Needham Virtual Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Needham Virtual Healthcare Conference on Tuesday, April 14, 2020 at 12:50 p.m. Eastern Time. Dr. Anido will provide an Aerie overview and business update.
Feb 24, 2020 07:30 am ET
Aerie Pharmaceuticals to Present at the Cowen 40th Annual Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Cowen 40th Annual Healthcare Conference on Monday, March 2, 2020 at 12:00 p.m. Eastern Time in Boston, MA. Dr. Anido will provide an Aerie overview and provide a business update.
Feb 20, 2020 04:01 pm ET
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results, Provides 2020 Guidance and Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2019, along with 2020 guidance and a general business update.
Feb 18, 2020 06:30 am ET
Aerie Pharmaceuticals Announces Appointment of Nina Ohara, PharmD, M.B.A, as Director, Marketing and Gregory Jones, CPA, as Director, Tax
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced the appointment of Nina Ohara, PharmD, M.B.A., as Director, Marketing, reporting to Deanne Melloy, Aerie’s Vice President of Marketing. Dr. Ohara will lead and support the development of strategies, programs and communication plans for the payer markets and manage all aspects of reimbursement to drive a
Feb 13, 2020 07:30 am ET
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, February 20, 2020
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye announced today that its fourth quarter and full year 2019 financial results will be released after the market closes on Thursday, February 20, 2020. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general
Feb 03, 2020 06:30 am ET
Aerie Pharmaceuticals Announces Appointment of Michelle Senchyna, Ph.D., as Vice President, Clinical Development and Medical Affairs
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced the appointment of Michelle Senchyna, Ph.D., as Vice President, Clinical Development and Medical Affairs, reporting to David A. Hollander, M.D., M.B.A., Aerie’s Chief Research & Development Officer. Dr. Senchyna will lead and direct the clinical development and medical affairs strategy for the Company.
Jan 21, 2020 06:30 am ET
Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced that its sterile fill production facility in Athlone, Ireland has received approval from U.S. Food and Drug Administration (FDA) to produce Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the U.S. market. The regulatory clearance of the plant follows a successful
Jan 02, 2020 06:30 am ET
Aerie Pharmaceuticals Announces Acceptance for Review of the Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Marketing Authorisation Application in Europe
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced that the European Medicines Agency (EMA) has accepted for review the marketing authorisation application (MAA) for Roclanda ® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. Roclanda® is currently marketed as Rocklatan® in the United States, where it is in
Dec 09, 2019 06:30 am ET
Aerie Pharmaceuticals Announces Appointment of Amine Sinmazisik as Director, Finance
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of Amine Sinmazisik as Director, Finance, reporting to Christopher Staten, Aerie’s Vice President of Finance. Ms. Sinmazisik will oversee the accounting and finance duties associated with revenue accounting and financial planning and analysis for the Company. She most recently held related positi
Dec 03, 2019 06:15 am ET
Aerie Pharmaceuticals Submits Marketing Authorisation Application for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in Europe
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that it has submitted the marketing authorisation application (MAA) for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% with the European Medicines Agency (EMA). Should the MAA for Roclanda® be accepted for review by the EMA, an opinion from the Committee for Medicin
Nov 26, 2019 06:30 am ET
Aerie Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Richard Rubino, Chief Financial Officer, will present in a fireside discussion at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 at 8:00 a.m. Eastern Time in New York, NY. Mr. Rubino will provide an Aerie overview and provide a business update.
Nov 21, 2019 06:30 am ET
Aerie Pharmaceuticals Receives European Commission Approval for Rhokiinsa® (netarsudil ophthalmic solution) 0.02%
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the European Commission (EC) has granted a marketing authorisation for Rhokiinsa® (netarsudil ophthalmic solution) 0.02% for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension.
Nov 18, 2019 06:30 am ET
Aerie Pharmaceuticals Announces Agreement to Acquire Avizorex Pharma, S.L. to Advance Its Dry Eye Program
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (“Aerie”), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced the signing of an agreement (the “Agreement”) for the acquisition of Avizorex Pharma, S.L. (“AVX Pharma” or “AVX”), a Spanish ophthalmic pharmaceutical company developing therapeutics for the treatment of dry eye disease.
Nov 12, 2019 07:30 am ET
Aerie Pharmaceuticals to Present at the Stifel 2019 Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 3:35 p.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and provide a business update.
Nov 06, 2019 04:01 pm ET
Aerie Pharmaceuticals Reports Third Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today reported financial results for the third quarter ended September 30, 2019 and provided a general business update.
Nov 05, 2019 06:30 am ET
Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudil Ophthalmic Solution in Phase 2 Study Conducted in Japan
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today reported positive topline results for the Company’s Phase 2 clinical trial evaluating netarsudil ophthalmic solution in Japanese patients. Netarsudil is a Rho kinase (ROCK) inhibitor specifically designed to increase outflow of aqueous humor through the trabecular meshwork, the eye’s primary drainage pathway. Netarsudil o
Oct 30, 2019 07:30 am ET
Aerie Pharmaceuticals to Announce Third Quarter 2019 Financial Results and Host Conference Call on Wednesday, November 6, 2019
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye announced today that its third quarter 2019 financial results will be released after the market closes on Wednesday, November 6, 2019. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update.
Oct 30, 2019 06:30 am ET
Aerie Pharmaceuticals Announces the Appointment of David A. Hollander, M.D., M.B.A., as Chief Research & Development Officer
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of David A. Hollander, M.D., M.B.A., as Chief Research & Development Officer, an executive officer position reporting to Vicente Anido, Jr., Ph.D., Aerie’s Chairman and Chief Executive Officer. Dr. Hollander will commence his employment at Aerie on November 11, 2019 and will direct the Company’s
Oct 24, 2019 06:30 am ET
Aerie Pharmaceuticals Completes Enrollment in the Phase 2 Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion Ahead of Schedule
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that patient enrollment in its Phase 2 clinical trial of AR-1105 in patients with macular edema due to retinal vein occlusion (RVO) is complete several weeks ahead of schedule. AR-1105 is an investigational sustained-release, bio-erodible intravitreal implant containing dexamethasone.
Oct 07, 2019 06:30 am ET
Aerie Pharmaceuticals Announces Appointment of Charlene E. Davis, Esq., as Vice President and Chief Compliance Officer
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of Charlene E. Davis, Esq., as Vice President and Chief Compliance Officer, reporting to John LaRocca, Aerie’s General Counsel. Ms. Davis will oversee the world wide compliance and data privacy functions for the Company. She most recently held a related position at Sun Pharmaceutical Industries,
Sep 25, 2019 07:30 am ET
Aerie Pharmaceuticals to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Richard Rubino, Chief Financial Officer, will present in a fireside discussion at the 2019 Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 2, 2019 at 3:35 p.m. Eastern Time in New York, NY. Mr. Rubino will provide an Aerie overview and provide a business update.
Sep 20, 2019 06:30 am ET
Aerie Pharmaceuticals Receives Positive CHMP Opinion for Rhokiinsa® in the European Union
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorisation application (MAA) for Rhokiinsa® (netarsudil ophthalmic solution) 0.02%. The recommended indication is the reduction of elevat
Sep 19, 2019 06:30 am ET
Aerie Pharmaceuticals Submits Prior Approval Supplement to the U.S. Food and Drug Administration to Allow Production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in its
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the submission of a prior approval supplement (PAS) to the U.S. Food and Drug Administration (FDA). If approved, the PAS will permit production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for sale in the United States in Aerie’s new manufacturing plant in Athlone, Irela
Sep 10, 2019 09:36 pm ET
Aerie Pharmaceuticals Announces Full Exercise by Initial Purchasers of Option to Purchase Additional $41.25 Million Aggregate Principal Amount of Aerie’s 1.50% Convertible Senior Notes Due 2024
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that the initial purchasers of the previously announced offering of Aerie’s 1.50% Convertible Senior Notes due 2024 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, have elected to fully exercise their option to purchase a
Sep 04, 2019 08:20 pm ET
Aerie Pharmaceuticals Upsizes and Prices Private Offering of $275 Million 1.50% Convertible Senior Notes Due 2024
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that it has priced $275 million aggregate principal amount of its 1.50% convertible senior notes due 2024 (the “notes”). The offering was increased to $275 million aggregate principal amount of notes from the previously announced offering size of $250 million aggregate principal amount of notes. The notes are b
Sep 03, 2019 04:01 pm ET
Aerie Pharmaceuticals to Offer $250 Million Convertible Senior Notes Due 2024
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that it proposes to offer $250 million aggregate principal amount of its convertible senior notes due 2024 (the “notes”), subject to market conditions and other factors. The notes are to be offered in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as
Sep 03, 2019 07:30 am ET
Aerie Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Richard Rubino, Chief Financial Officer, will present at the H.C. Wainwright Global Investment Conference on Tuesday, September 10, 2019 at 9:35 a.m. Eastern Time in New York, NY. Mr. Rubino will provide an Aerie overview and provide a business update.
Aug 26, 2019 06:30 am ET
Aerie Pharmaceuticals Announces Appointment of Luis Vargas, M.D., as Medical Director, Medical Affairs
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of Luis Vargas, M.D., as Medical Director, Medical Affairs, reporting to Welyn Bui, PharmD, Aerie’s Vice President of Medical Affairs. Dr. Vargas will oversee the organizational planning and operational needs of medical affairs at Aerie. He most recently held related positions at Revision Optics
Aug 20, 2019 06:30 am ET
Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial of AR-13503 Sustained Release Intravitreal Implant in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edem
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced the commencement of patient dosing in a first-in-human clinical trial of AR-13503 Sustained Release (SR) Implant in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
Aug 07, 2019 04:01 pm ET
Jul 25, 2019 07:30 am ET
Aerie Pharmaceuticals to Announce Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, August 7, 2019
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye announced today that its second quarter 2019 financial results will be released after the market closes on Wednesday, August 7, 2019. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update.
Jul 09, 2019 06:30 am ET
Aerie Pharmaceuticals Completes Enrollment of the Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Months Ahead of Schedule
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that enrollment for its Phase 2 clinical trial of netarsudil ophthalmic solution in Japan is complete, a milestone reached several months earlier than previously anticipated.
Jun 17, 2019 06:30 am ET
Aerie Pharmaceuticals Announces Appointment of Jeffrey Calabrese, CPA, as Director of Accounting
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retinal diseases and other diseases of the eye today announced
the appointment of Jeffrey Calabrese, CPA, as Director of Accounting,
reporting to Christopher Staten, Aerie’s Vice President of Finance. Mr.
Calabrese will lead external financial reporting, technical accounting
and equity accounting. He most recently held relate
Jun 11, 2019 07:30 am ET
Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retinal diseases and other diseases of the eye today announced
that Richard Rubino, Chief Financial Officer, will present an Aerie
overview and provide a business update at two upcoming investor
conferences:
May 28, 2019 07:30 am ET
Aerie Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retinal diseases and other diseases of the eye today announced
that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer,
will present at the Jefferies 2019 Healthcare Conference on Tuesday,
June 4, 2019 at 2:30 p.m. Eastern Time in New York, NY. Dr. Anido will
provide an Aerie overview and provide a business updat
May 07, 2019 04:01 pm ET
Aerie Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retinal diseases and other diseases of the eye, today reported
financial results for the first quarter ended March 31, 2019, along with
a general business update.
May 02, 2019 06:33 pm ET
Aerie Pharmaceuticals Announces Additional Undrawn $100M Credit Facility with Deerfield Management, Increasing Availability to $200M
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with open-angle glaucoma, retinal diseases and other diseases
of the eye, today announced that it has entered into an amendment of its
existing credit agreement with certain affiliates of Deerfield
Management Company L.P. (Deerfield).
May 01, 2019 06:30 am ET
Aerie Pharmaceuticals Announces U.S. Launch of Rocklatan® and Increase in Rhopressa® Medicare Part D Coverage to Approximately 75% of Lives
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retinal diseases and other diseases of the eye, today
announced that it has launched Rocklatan® (netarsudil and
latanoprost ophthalmic solution) 0.02%/0.005% into the United States
glaucoma market. Rocklatan® is now with national and regional
U.S. pharmaceutical wholesalers, and patients can fill prescri
Apr 30, 2019 07:30 am ET
Aerie Pharmaceuticals to Announce First Quarter 2019 Financial Results and Host Conference Call on Tuesday, May 7, 2019
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retinal diseases and other diseases of the eye announced today
that its first quarter 2019 financial results will be released after the
market closes on Tuesday, May 7, 2019. Following the release, the
Company will host a live conference call and webcast at 5:00 p.m.
Eastern Time to discuss the Company’s financial results and
Apr 25, 2019 06:30 am ET
Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-13503 Sustained Release Implant
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retinal diseases and other diseases of the eye, today
announced that the U.S. Food and Drug Administration (FDA) has reviewed
the Investigational New Drug Application (IND) for AR-13503, a novel
multi-kinase (Rho kinase/Protein kinase C (ROCK/PKC)) inhibitor
sustained-release implant (the AR-13503 implant) and it is now in
Apr 02, 2019 07:30 am ET
Aerie Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retinal diseases and other diseases of the eye today announced
that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer,
will present in a fireside discussion at the 18th Annual
Needham Healthcare Conference on Tuesday, April 9, 2019 at 1:30 p.m.
Eastern Time in New York, NY. Dr. Anido will provide an A
Apr 01, 2019 06:30 am ET
Aerie Pharmaceuticals Announces Appointment of Gianluca Corbinelli as Chief Commercial Officer - Europe
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retinal diseases and other diseases of the eye today announced
the appointment of Gianluca Corbinelli as Chief Commercial Officer -
Europe, reporting to Thomas Mitro, Aerie’s President and Chief Operating
Officer. Mr. Corbinelli will be responsible for overseeing the execution
of all aspects of Aerie’s commercialization activ
Mar 25, 2019 06:30 am ET
Aerie Pharmaceuticals Announces Four Appointments
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retinal diseases and other diseases of the eye today announced
the appointment of David Ellis, Ph.D., as Director, Chemistry, reporting
to Mitchell deLong, Ph.D., Aerie’s Vice President of Chemistry. Dr.
Ellis will be responsible for advancing the Company’s creation and
optimization of new chemical entities to support the gro
Mar 21, 2019 06:30 am ET
Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Designed to Support Requirements for Future Regulatory Filing
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with open-angle glaucoma, retinal diseases and other diseases
of the eye, today announced the commencement of patient dosing in its
Phase 2 clinical trial designed in accordance with the requirements of
Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) to support
potential regulatory submission of netarsudil ophthalmic solution
Mar 18, 2019 06:30 am ET
Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with open-angle glaucoma, retinal diseases and other diseases
of the eye, today announced the commencement of patient dosing in a
Phase 2 clinical trial of AR-1105, its investigational dexamethasone
intravitreal implant, in patients with macular edema due to retinal vein
occlusion (RVO).
Mar 12, 2019 06:30 pm ET
Aerie Pharmaceuticals Announces Full-Year 2019 Net Revenue and Net Cash Burn Guidance
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retinal diseases and other diseases of the eye, today
announced full-year 2019 net revenue and net cash burn guidance.
Mar 12, 2019 06:20 pm ET
Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan™ (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glau
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an
ophthalmic pharmaceutical company focused on the discovery, development
and commercialization of first-in-class therapies for the treatment of
patients with open-angle glaucoma, retinal diseases and other diseases
of the eye, today announced that the U.S. Food and Drug Administration
(FDA) has approved Rocklatan™ (netarsudil and latanoprost
ophthalmic solution) 0.02%/0.005% to reduce elevated intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular
Mar 05, 2019 07:30 am ET
Aerie Pharmaceuticals to Present at Two Investor Conferences in March
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retinal diseases and other diseases of the eye today announced
that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer,
will present an Aerie overview and provide a business update in a
fireside discussion at the following conferences in March.
Mar 01, 2019 08:25 am ET
New Research Coverage Highlights Micron Technology, Varian Medical, St. Joe, Himax Technologies, Aerie Pharmaceuticals, and Hexcel — Consolidated Revenues, Company Growth, and Expectations for 2019
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Micron Technology, Inc. (NASDAQ:MU), Varian Medical Systems, Inc. (NYSE:VAR),...
Feb 25, 2019 04:01 pm ET
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results, Provides 2019 Cash Burn Guidance and Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retinal diseases and other diseases of the eye, today reported
financial results for the fourth quarter and full year ended
December 31, 2018, along with 2019 cash burn guidance and a general
business update.
Feb 19, 2019 07:30 am ET
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Monday, February 25, 2019
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retinal diseases and other diseases of the eye announced today
that its fourth quarter and full year 2018 financial results will be
released after the market closes on Monday, February 25, 2019. Following
the release, the Company will host a live conference call and webcast at
5:00 p.m. Eastern Time to discuss the Company’s f
Jan 17, 2019 06:30 am ET
Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-1105 (Dexamethasone Intravitreal Implant)
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retina diseases and other diseases of the eye today announced
that the U.S. Food and Drug Administration (FDA) has reviewed the
Investigational New Drug Application (IND) for AR-1105 (dexamethasone
intravitreal implant) and it is now in effect, allowing Aerie to
initiate human studies in the treatment of macular edema due to
Jan 04, 2019 06:30 am ET
Aerie Pharmaceuticals Announces Positive Topline Results of Netarsudil Ophthalmic Solution in Pilot Phase 2 Study Supporting Clinical Development in Japan
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retina diseases and other diseases of the eye today announced
the topline results of its pilot Phase 2 study of netarsudil ophthalmic
solution in a Japanese-American population. The study was designed in
accordance with the requirements of Japan’s PMDA (Pharmaceuticals and
Medical Devices Agency) to support the potential regu
Jan 02, 2019 06:30 am ET
Aerie Pharmaceuticals Announces Appointment of Ami Bavishi as Director, Investor Relations and Vincent Santucci, Pharm.D., as Director, Scientific Market Access
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retina diseases and other diseases of the eye, today announced
the appointment of Ami Bavishi as Director, Investor Relations,
reporting to Richard Rubino, Aerie’s Chief Financial Officer. Ms.
Bavishi will drive all of Aerie’s investor relations activities, and
joins Aerie from Burns McClellan, a public relations and investor
Dec 04, 2018 07:20 am ET
Investor Expectations to Drive Momentum within Mirati Therapeutics, comScore, Nuance Communications, Carnival, Aerie Pharmaceuticals, and TrueCar — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mirati Therapeutics, Inc. (NASDAQ:MRTX), comScore, Inc. (NASDAQ:SCOR),...
Nov 07, 2018 07:30 am ET
Aerie Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retina diseases and other diseases of the eye, today announced
that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer,
will present in a fireside discussion at the Stifel 2018 Healthcare
Conference on Tuesday, November 13, 2018 at 10:15 a.m. Eastern Time in
New York, NY. Dr. Anido will provide an Aerie overview
Nov 06, 2018 04:01 pm ET
Aerie Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retina diseases and other diseases of the eye, today reported
financial results for the third quarter ended September 30, 2018, along
with a general business update.
Oct 30, 2018 07:30 am ET
Aerie Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company),
announced today that its third quarter 2018 financial results will be
released after the market closes on Tuesday, November 6, 2018. Following
the release, the Company will host a live conference call and webcast at
5:00 p.m. Eastern Time to discuss the Company’s financial results and
provide a general business update.
Oct 25, 2018 08:30 am ET
Report: Exploring Fundamental Drivers Behind Invitae, Aerie Pharmaceuticals, Gevo, Global Medical REIT, Cyclacel Pharmaceuticals, and Toll Brothers — New Horizons, Emerging Trends, and Upcoming Develo
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Invitae Corporation (NYSE:NVTA), Aerie Pharmaceuticals, Inc....
Oct 23, 2018 06:30 am ET
Aerie Pharmaceuticals Establishes GMP PRINT® Production Facility in an Expanded Global Headquarters
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retinal diseases and other diseases of the eye, today
announced that it has built and commenced operation of its GMP (Good
Manufacturing Practices)-validated manufacturing facility for production
of ophthalmic implants using the proprietary PRINT® (Particle
Replication in Non-wetting Templates) Technology platform
Oct 09, 2018 06:30 am ET
Aerie Pharmaceuticals, Inc. Announces Drug Application for Regulatory Approval Accepted for Review in Europe
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retina diseases and other diseases of the eye, today reported
that the EMA has accepted for review the MAA for Rhokiinsa®
(netarsudil ophthalmic solution) 0.02%. Rhokiinsa® is
currently marketed as Rhopressa® in the United States and is
indicated for the reduction of elevated intraocular press
Sep 25, 2018 07:30 am ET
Aerie Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retina diseases and other diseases of the eye, today announced
that Richard Rubino, Chief Financial Officer, will present at the Cantor
Fitzgerald 2018 Global Healthcare Conference on Tuesday, October 2, 2018
at 2:15 p.m. Eastern Time in New York, NY. Mr. Rubino will provide an
Aerie overview and business update.
Sep 24, 2018 06:30 am ET
Aerie Pharmaceuticals Announces Appointment of Damien Monaghan, Quality Director
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retina diseases and other diseases of the eye, today announced
the appointment of Damien Monaghan, Quality Director, reporting to
Finbar O’Neill, EU Director, Quality & Regulatory Compliance. Mr.
Monaghan will lead quality assurance and quality control operations for
Aerie’s manufacturing plant in Athlone, Ireland. Mr. Monagh
Sep 13, 2018 06:30 am ET
Aerie Pharmaceuticals to Present at Ophthalmology Futures Forums in Vienna, Austria
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retina diseases and other diseases of the eye, today announced
that Richard Rubino, Chief Financial Officer, will present at the
Ophthalmology Futures European Forum held prior to the 36th Congress of
the European Society of Cataract and Refractive Surgeons on Thursday,
September 20, 2018 at 9:57 a.m. Central European Time i
Sep 12, 2018 04:01 pm ET
Aerie Pharmaceuticals Appoints David W. Gryska to the Company’s Board of Directors
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retina diseases and other diseases of the eye, today
announced that David W. Gryska has been appointed to the Company’s Board
of Directors and will also be a member of the Audit Committee of the
Board. David brings extensive executive level healthcare-focused and
financial leadership experience from large global biopharmaceut
Sep 11, 2018 04:01 pm ET
Aerie Pharmaceuticals Announces Appointment of Robert Finan as Director of Finance
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retina diseases and other diseases of the eye, today announced
the appointment of Robert Finan, Director of Finance, reporting to
Christopher Staten, Vice President of Finance. Mr. Finan will lead
Aerie’s finance, operations and strategy activities for Aerie’s
manufacturing plant in Athlone, Ireland. Mr. Finan most recently h
Sep 10, 2018 06:30 am ET
Aerie Pharmaceuticals Announces Appointment of Thomas A. Shepard as Vice President, Implant Manufacturing
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retina diseases and other diseases of the eye, today announced
the appointment of Thomas A. Shepard as Vice President, Implant
Manufacturing, reporting to Casey Kopczynski, Ph.D., Aerie’s Chief
Scientific Officer. Mr. Shepard will lead Aerie’s implant manufacturing
facility in Durham, North Carolina, including responsibility
Sep 05, 2018 07:30 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Aerie Pharmaceuticals, BioScrip, Celsion, Primoris Services, Cyclacel Pharmaceuticals, and Barnes Group — New Research Emphasizes Ec
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), BioScrip, Inc. (NASDAQ:BIOS),...
Aug 20, 2018 06:30 am ET
Aerie Pharmaceuticals Announces Appointment of Jeffrey White, Ph.D. as Director, Toxicology and Pharmacokinetics
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retina diseases and other diseases of the eye, today announced
the appointment of Jeffrey White, Ph.D. as Director, Toxicology and
Pharmacokinetics, reporting to Eric Carlson, Ph.D., Aerie’s Vice
President of Research and Development. Dr. White will have operational
and scientific responsibility for Aerie’s nonclinical develo
Aug 16, 2018 08:20 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within inTest, Hooker Furniture, American Public Education, Gevo, Envestnet, and Aerie Pharmaceuticals — New Research Emphasizes Economic G
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of inTest Corporation (NYSE:INTT), Hooker Furniture Corporation...
Aug 15, 2018 06:30 am ET
Aerie Pharmaceuticals Reports Topline Result from Rhopressa® Mechanism of Action Study
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retina diseases and other diseases of the eye, today
announced topline efficacy results from a double-masked, randomized,
placebo-controlled study (AR-13324-CS206; NCT03233308) designed to
evaluate the effect of Rhopressa® (netarsudil ophthalmic
solution) 0.02% on aqueous humor dynamics in patients with open-angle
Aug 08, 2018 04:01 pm ET
Aerie Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retina diseases and other diseases of the eye, today reported
financial results for the second quarter ended June 30, 2018, along with
a general business update.
Aug 02, 2018 07:30 am ET
Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retina diseases and other diseases of the eye, today announced
that Richard Rubino, Chief Financial Officer, will present in a fireside
chat discussion at the Canaccord Genuity Growth Conference on Thursday,
August 9, 2018 at 1:30 p.m. Eastern Time in Boston, MA. Mr. Rubino will
provide an Aerie overview and business update.
Aug 01, 2018 07:30 am ET
Aerie Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Wednesday, August 8, 2018
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company),
announced today that its second quarter 2018 financial results will be
released after the market closes on Wednesday, August 8, 2018. Following
the release, the Company will host a live conference call and webcast at
5:00 p.m. Eastern Time to discuss the Company’s financial results and
provide a general business update.
Aug 01, 2018 06:30 am ET
Aerie Pharmaceuticals, Inc. and DSM Biomedical, Inc. Expand Collaboration Agreement Focused on Novel Drug Delivery Technology in Ophthalmology
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retina diseases and other diseases of the eye, and DSM
Biomedical, Inc., a global solutions provider in biomedical science and
regenerative medicine, today reported that they have expanded their
collaborative research, development, and license agreement.
Jul 23, 2018 07:30 am ET
Aerie Pharmaceuticals Announces Deerfield’s Conversion of Convertible Notes into Aerie Common Stock and Establishment of an Undrawn $100M Credit Facility with Deerfield
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retina diseases and other diseases of the eye, today announced
that the $125 million of senior secured convertible notes held by
affiliates (the “holders”) of Deerfield Management Company L.P.
(“Deerfield”) since September 2014 have been fully converted into
5,040,323 shares of Aerie common stock in accordance with their term
Jul 23, 2018 06:30 am ET
Aerie Pharmaceuticals Announces Early Notification of FDA Acceptance of NDA Submission for Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% with PDUFA Date Set for March 14, 2019
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retina diseases and other diseases of the eye, today reported
that it has received the “Day 74” notification from the U.S. Food and
Drug Administration (FDA) earlier than scheduled, the FDA has completed
its initial 60-day review of the NDA (new drug application) for
Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02
Jul 16, 2018 06:30 am ET
Aerie Pharmaceuticals Announces Appointment of Randall Brown as Director, Payer Marketing
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma and other diseases of the eye, today announced the appointment
of Randall Brown as Director, Payer Marketing, reporting to Deanne
Melloy, Aerie’s Vice President of Marketing. Mr. Brown will support the
ongoing development and execution of strategies, programs and
communication activities for the payer markets. Mr. Brown previo
Jun 18, 2018 06:30 am ET
Aerie Pharmaceuticals Announces Appointment of William Coppola as Intellectual Property Counsel
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma and other diseases of the eye, today announced the appointment
of William Coppola as Intellectual Property Counsel, reporting to John
LaRocca, Aerie’s General Counsel. Mr. Coppola will oversee intellectual
property matters both domestically and internationally on behalf of the
Company. Mr. Coppola previously held related posit
Jun 14, 2018 07:30 am ET
Aerie Pharmaceuticals to Present at the JMP Securities 2018 Life Science Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma and other diseases of the eye, today announced that Richard
Rubino, Chief Financial Officer, will present in a fireside chat
discussion at the JMP Securities 2018 Life Science Conference on
Thursday, June 21, 2018 at 2:00pm Eastern Time in New York, NY. Mr.
Rubino will provide an Aerie overview and business update.
Jun 06, 2018 07:30 am ET
Aerie Pharmaceuticals to Present at the NASDAQ 38th Investor Conference
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma and other diseases of the eye, today announced that Richard
Rubino, Chief Financial Officer, will present at the NASDAQ 38th
Investor Conference on Tuesday, June 12, 2018 at 9:00am British Summer
Time in London, UK. Mr. Rubino will provide an Aerie overview and
business update.
May 31, 2018 07:30 am ET
Aerie Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma and other diseases of the eye, today announced that Vicente
Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present at
the Jefferies 2018 Global Healthcare Conference on Tuesday, June 5, 2018
at 4:30pm Eastern Time in New York, NY. Dr. Anido will provide an Aerie
overview and business update.
May 30, 2018 06:30 am ET
Aerie Pharmaceuticals Announces Appointment of Lily Nguyen as Director, Project Management
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma and other diseases of the eye, today announced the appointment
of Lily Nguyen as Director, Project Management, reporting to Kenneth
Ruettimann, Ph.D., Aerie’s Vice President of Manufacturing. Ms. Nguyen
will direct strategic plan development and oversee ongoing project
progress in the manufacturing department. Ms. Nguyen previ
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.